MDT-AP-1252
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 120
- os_event
- false
- age_years
- 10
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.027758103
- umap2_2d
- 6.348877124
- umap1_3d
- 1.998274158
- umap2_3d
- -0.078826454
- umap3_3d
- -3.550077553
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.220
- E2F_TARGETS+0.220
- SPERMATOGENESIS+0.160
- KRAS_SIGNALING_DN+0.130
- G2M_CHECKPOINT+0.110
- XENOBIOTIC_METABOLISM+0.050
- MITOTIC_SPINDLE+0.030
- PANCREAS_BETA_CELLS-0.010
- PI3K_AKT_MTOR_SIGNALING-0.010
- FATTY_ACID_METABOLISM-0.030
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.460
- MYC_TARGETS_V2-0.450
- INTERFERON_GAMMA_RESPONSE-0.420
- MTORC1_SIGNALING-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- ANDROGEN_RESPONSE-0.370
- MYC_TARGETS_V1-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- UV_RESPONSE_DN-0.370
- IL6_JAK_STAT3_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.905 |
| 2 | BS_KN92S7YQ | medulloblastoma | — | 0.898 |
| 3 | SRR1341605 | GTEX | — | 0.888 |
| 4 | SRR1436444 | GTEX | — | 0.884 |
| 5 | MDT-AP-2067 | Med | Medulloblastoma | 0.881 |
| 6 | BS_4W68NV3M | medulloblastoma | — | 0.880 |
| 7 | MDT-AP-0350 | Med | Medulloblastoma | 0.880 |
| 8 | BS_QRDT19KS | medulloblastoma | — | 0.878 |
| 9 | MDT-AP-2068 | Med | Medulloblastoma | 0.877 |
| 10 | SRR1467813 | GTEX | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |